Premium
The clinical trial of an alkylating agent with a short half‐life designed for intra‐arterial chemotherapy
Author(s) -
Meyza J.,
Cobb L. M.
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197102)27:2<369::aid-cncr2820270220>3.0.co;2-5
Subject(s) - medicine , chemotherapy , drug , clinical trial , malignancy , toxicity , bone marrow , pharmacology , oncology , surgery
P ‐(2,3‐di (2‐bromoethylthio)‐ n ‐propyloxy) benzoic acid (CB 1850) is an alkylating agent with a half‐life of 4.8 seconds designed for intra‐arterial chemotherapy. The results of a clinical trial of this drug in 39 patients with malignancy are given. The drug was found to have antitumor activity. Concerning the destruction of tumor, the results were comparable with any of the cytotoxic agents presently used for intra‐arterial infusion. In many cases, the drug produced alleviation of pain where other cytotoxic agents used in patients with similar tumors failed to produce this effect. There was no toxicity to the sensitive elements in bone marrow and intestine.